DK3941443T3 - Depotsammensætning, som omfatter tapentadol oxalat og fremgangsmåde til formulering heraf - Google Patents
Depotsammensætning, som omfatter tapentadol oxalat og fremgangsmåde til formulering heraf Download PDFInfo
- Publication number
- DK3941443T3 DK3941443T3 DK20721145.9T DK20721145T DK3941443T3 DK 3941443 T3 DK3941443 T3 DK 3941443T3 DK 20721145 T DK20721145 T DK 20721145T DK 3941443 T3 DK3941443 T3 DK 3941443T3
- Authority
- DK
- Denmark
- Prior art keywords
- tapentadol
- oxalate
- formulation
- spot composition
- spot
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title 1
- 229960005126 tapentadol Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20190100138A GR1009751B (el) | 2019-03-22 | 2019-03-22 | Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει οξαλικη ταπενταδολη και μεθοδος παρασκευης αυτου |
| PCT/EP2020/025139 WO2020192969A1 (en) | 2019-03-22 | 2020-03-20 | Sustained release composition comprising tapentadol oxalate and method of preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3941443T3 true DK3941443T3 (da) | 2024-03-18 |
Family
ID=70456722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20721145.9T DK3941443T3 (da) | 2019-03-22 | 2020-03-20 | Depotsammensætning, som omfatter tapentadol oxalat og fremgangsmåde til formulering heraf |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220202720A1 (da) |
| EP (1) | EP3941443B1 (da) |
| AU (1) | AU2020248971A1 (da) |
| BR (1) | BR112021018896A2 (da) |
| CA (1) | CA3134455A1 (da) |
| DK (1) | DK3941443T3 (da) |
| FI (1) | FI3941443T3 (da) |
| GR (1) | GR1009751B (da) |
| LT (1) | LT3941443T (da) |
| PT (1) | PT3941443T (da) |
| RS (1) | RS65287B1 (da) |
| WO (1) | WO2020192969A1 (da) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| FR2936709B1 (fr) | 2008-10-02 | 2012-05-11 | Ethypharm Sa | Comprimes alcoolo-resistants. |
| EP2555756B1 (en) | 2010-04-07 | 2018-08-22 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| US20130059010A1 (en) | 2010-05-14 | 2013-03-07 | Ethypharm | Alcohol-resistant oral pharmaceutical form |
| EP2714015B1 (en) | 2011-06-01 | 2017-03-15 | FMC Corporation | Controlled release solid dose forms |
| JP2014524925A (ja) * | 2011-07-29 | 2014-09-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時薬剤放出を提供するタンパーレジスタント錠剤 |
| EP3122337A4 (en) * | 2014-03-26 | 2017-11-08 | Sun Pharma Advanced Research Company Ltd | Abuse deterrent immediate release coated reservoir solid dosage form |
| WO2015157150A1 (en) * | 2014-04-07 | 2015-10-15 | Banner Life Sciences Llc | Opioid abuse-deterrent controlled release formulations |
| US20180303757A1 (en) * | 2015-10-23 | 2018-10-25 | Kashiv Pharma Llc | Enhanced abuse-deterrent formulations of oxycodone |
| US20190054024A1 (en) * | 2017-08-16 | 2019-02-21 | HUMANWELL PHARMACEUTICAL US, Inc. | Solid Dosage Forms |
-
2019
- 2019-03-22 GR GR20190100138A patent/GR1009751B/el active IP Right Grant
-
2020
- 2020-03-20 BR BR112021018896A patent/BR112021018896A2/pt unknown
- 2020-03-20 PT PT207211459T patent/PT3941443T/pt unknown
- 2020-03-20 LT LTEPPCT/EP2020/025139T patent/LT3941443T/lt unknown
- 2020-03-20 EP EP20721145.9A patent/EP3941443B1/en active Active
- 2020-03-20 CA CA3134455A patent/CA3134455A1/en active Pending
- 2020-03-20 FI FIEP20721145.9T patent/FI3941443T3/fi active
- 2020-03-20 WO PCT/EP2020/025139 patent/WO2020192969A1/en active Application Filing
- 2020-03-20 AU AU2020248971A patent/AU2020248971A1/en active Pending
- 2020-03-20 US US17/441,531 patent/US20220202720A1/en active Pending
- 2020-03-20 DK DK20721145.9T patent/DK3941443T3/da active
- 2020-03-20 RS RS20240301A patent/RS65287B1/sr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3134455A1 (en) | 2020-10-01 |
| GR1009751B (el) | 2020-05-29 |
| RS65287B1 (sr) | 2024-04-30 |
| LT3941443T (lt) | 2024-03-25 |
| FI3941443T3 (fi) | 2024-03-15 |
| EP3941443B1 (en) | 2023-12-13 |
| AU2020248971A1 (en) | 2021-11-18 |
| PT3941443T (pt) | 2024-03-15 |
| US20220202720A1 (en) | 2022-06-30 |
| WO2020192969A1 (en) | 2020-10-01 |
| BR112021018896A2 (pt) | 2021-11-30 |
| EP3941443A1 (en) | 2022-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3775091T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåder til fremstilling, oplagring og anvendelse deraf | |
| DK3911647T3 (da) | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan | |
| DK3442973T3 (da) | Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme | |
| DK3328843T3 (da) | 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning | |
| DK3362445T3 (da) | Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed | |
| DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3330259T3 (da) | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne | |
| DK3524603T3 (da) | Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
| DK3562810T3 (da) | Benzhydroxamsyre-derivater som selektive hdac6-inhibitorer | |
| DK3388420T3 (da) | Quinolin-forbindelser, metode til fremstilling deraf og anvendelse deraf som urattransporter-hæmmende lægemiddel | |
| EP3825322C0 (en) | POLYPEPTIDE COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | |
| DK3744316T3 (da) | Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| IL283755A (en) | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors, compositions comprising same and uses thereof | |
| CL2022000373A1 (es) | (divisional solicitud 2021-1835) neoantígenos prostáticos y sus usos. | |
| DK3604304T3 (da) | Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme | |
| IT201900004799A1 (it) | Proiettore, preferibilmente da palcoscenico, e metodo per operare detto proiettore | |
| DK3797107T3 (da) | Heterokondenserede pyridonforbindelser og anvendelse deraf som idh- hæmmere | |
| DK3404024T3 (da) | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser | |
| EP3677126A4 (en) | COMPOSITION OF AGE INHIBITORS, ITS USE, PROCESS OF PREPARATION AND ITS FORMULATION | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| EP3646855A4 (en) | COMPOSITION FOR SOLID PREPARATION FOR ORAL USE INCLUDING A PROTON PUMP INHIBITOR, SOLID PREPARATION FOR ORAL USE INCLUDING IT, AND PROCESS FOR PREPARATION | |
| DK3568396T3 (da) | Hidtil ukendte amino-imidazopyridinderivater som janus kinase-inhibitorer og farmaceutisk anvendelse deraf | |
| IL289586A (en) | pi4kiii alpha micromolecule inhibiting preparation, method for its preparation and use | |
| DK3941443T3 (da) | Depotsammensætning, som omfatter tapentadol oxalat og fremgangsmåde til formulering heraf | |
| DK3455216T3 (da) | Pyridinylderivater, farmaceutiske sammensætninger og anvendelser deraf som aoc3-inhibitorer |